Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Douglas Smith

Showing results (71-80 of 203) with videos related to

Pageof 21
Sort By:
Leukemia Research|November 12, 2021
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CMLJonathan A Webster, Tara M Robinson, Amanda L Blackford, et al.
Current Medical Research and Opinion|April 10, 2019
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemiaJorge E Cortes, Bogdan Muresan, Carla Mamolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid LeukemiaJoshua F Zeidner, Daniel J Lee, Mark Frattini, et al.
Journal of Palliative Medicine|May 25, 2017
A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete RemissionM Jennifer Cheng, B Douglas Smith, Christopher S Hourigan, et al.
International Journal of Hematology|October 1, 2022
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequencyMichael J Hochman, B Douglas Smith, Theodoros Karantanos, et al.
Blood|May 16, 2002
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivoMark Levis, Jeffrey Allebach, Kam-Fai Tse, et al.
Clinical and Translational Science|April 28, 2018
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 RelationshipTao Liu, Vijay Ivaturi, Philip Sabato, et al.
British Journal of Haematology|July 27, 2005
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitorsGreg R Angstreich, William Matsui, Carol Ann Huff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvementYvette L Kasamon, Richard J Jones, Steven Piantadosi, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 27, 2006
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assayMing Zhao, Michelle A Rudek, Ping He, et al.
Pageof 21

Showing results (71-80 of 203) with videos related to

Sort By:
Pageof 21
Leukemia Research|November 12, 2021
A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CMLJonathan A Webster, Tara M Robinson, Amanda L Blackford, et al.
Current Medical Research and Opinion|April 10, 2019
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemiaJorge E Cortes, Bogdan Muresan, Carla Mamolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2020
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid LeukemiaJoshua F Zeidner, Daniel J Lee, Mark Frattini, et al.
Journal of Palliative Medicine|May 25, 2017
A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete RemissionM Jennifer Cheng, B Douglas Smith, Christopher S Hourigan, et al.
International Journal of Hematology|October 1, 2022
Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequencyMichael J Hochman, B Douglas Smith, Theodoros Karantanos, et al.
Blood|May 16, 2002
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivoMark Levis, Jeffrey Allebach, Kam-Fai Tse, et al.
Clinical and Translational Science|April 28, 2018
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 RelationshipTao Liu, Vijay Ivaturi, Philip Sabato, et al.
British Journal of Haematology|July 27, 2005
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitorsGreg R Angstreich, William Matsui, Carol Ann Huff, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 1, 2005
High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvementYvette L Kasamon, Richard J Jones, Steven Piantadosi, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 27, 2006
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assayMing Zhao, Michelle A Rudek, Ping He, et al.
Pageof 21